Relmada's depression drug fails to meet late-stage study goal (updated)

Relmada Therapeutics

13/10/2022 12:28

(Adds details on trial)
       Oct 13 (Reuters) - Relmada Therapeutics Inc  RLMD.O 
said on Thursday its therapy to treat major depressive disorder
did not meet the main goal of a late-stage study.
     The drug, REL-1017, did not show statistically significant
improvement in symptoms of depression when compared to a
placebo.
    Relmada will continue to study REL-1017, its lead treatment,
as an adjuntive or in combination with other depression drugs. 
    Major depressive disorder is a chronic condition that makes
patients feel low, experience guilt and worthlessness. In
extreme cases, it may lead to suicide.
    Shares of the company, which had a market capitalization of
nearly $1 billion as of Wednesday's close, were halted in
premarket trading.
 (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Khushi.Mandowara@thomsonreuters.com;))